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Abstract
Background: Given that a deubiquitinating enzyme, ubiquitin-specific protease 2a (USP2a), regulates ubiquitination,
trafficking, and degradation of EGFR, which plays a critical role in bladder cancer, in this study, we aimed to
quantify the USP2a gene expression, and to determine the possibility that USP2a can be used for bladder cancer
diagnosis.
Methods: Using two independent cohorts (cohort 1, n = 339 in total; cohort 2, n = 140 in total) consisting of
human bladder tissues from BC patients and normal controls, we analyzed the gene expression levels of USP2a.
A quantitative real-time PCR amplification was performed using a Rotor Gene 6000 instrument to quantify the
expression of USP2a mRNA.
Results: A comparison of 305 bladder cancers and 34 age-matched controls showed an 81.4 % reduction in
USP2a expression in bladder cancers as compared to normal bladder tissues (p < 0.001). In the independent
cohort consisting of 140 BC tissues and matched adjacent normal bladder tissues, the levels of USP2a in the
specimens of BC patients were reduced by 86.9 % as compared to matched surrounding normal specimens from
the same patients (p < 0.001). Furthermore, there was 36.3 % reduction of USP2a gene expression in muscle
invasive bladder cancer (MIBC, n = 121), compared to non muscle invasive bladder cancer (NMIBC,
n = 184) (p = 0.004). Lastly, USP2a mRNA expression was significantly reduced in higher stages of MIBC patients
(p = 0.024), but not in NMIBC patients.
Conclusions: Our findings suggest that USP2a mRNA may be considered as a diagnostic marker candidate for
bladder cancer, in particular, to stratify MIBC patients with a more invasive phenotype.
Background
Bladder cancer (BC) is the second most common geni-
tourinary malignancy and the fourth most common
cancer among American and European [1–4]. More
than 90 % of bladder cancers diagnosed in the US are
urothelial carcinoma, which are mostly papillary, well-, or
moderately-differentiated non-muscle invasive bladder
cancer (NMIBC) [5]. Within 2 years after standard treat-
ment, approximately 20–30 % of the NMIBC patients will
show recurrence that results in the progression to muscle
invasive disease (MIBC) [5], resulting in poor long-term
survival and frequent metastases into regional lymph
nodes (78 %), liver (38 %), lung (36 %), bone, adrenal gland
or intestine [6].
A promising finding by a research team led by François
Radvanyi, along with previous studies from this group and
from other laboratories [7–9], provided persuasive evi-
dence that a certain subtype of BC—“basal-like
BC”—displays activation of EGFR signaling pathway
and better responsiveness to EGFR inhibitors. EGFR is
known to be de-ubiqutunated by ubiquitin-specific pro-
tease 2a (USP2a) [10]. In particular, in BC cell culture
system, USP2a de-ubiquitinates a cell cycle regulator,
cyclin A1, thereby promoting cell proliferation [11],
and USP2a regulates expression levels of fatty acid syn-
thase (FASN), MDM2, MDM4, MDMX, and cyclin D1
[12–16]. However, USP2a has been also known to have
a distinct function as a signal mediator of tumor necro-
sis factor-α (TNF-α)-induced cell death [17], suggesting
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that USP2a function can be different in terms of cell
context. Therefore, we hypothesized that USP2a expres-
sion correlates with bladder cancer progression and tested
the hypothesis using our two unique cohorts consisting
of patient-derived NMIBC and MIBC bladder tumor
specimens.
Methods
Ethics Statement
The Ethics Committee of Chungbuk National University
approved the protocol used for this study. Written in-
formed consent was obtained from each subject. The
Institutional Review Board of Chungbuk National Uni-
versity approved collection and analysis of all samples.
Patients and Tissue Samples
All primary tumor samples from patients who under-
went TUR or radical cystectomy were histologically veri-
fied as urothelial carcinoma at Chungbuk National
University in South Korea [18, 19]. Non-cancerous sur-
rounding tissue was obtained from tissue at least 3 cm
from the tumor and normal bladder mucosa was har-
vested from patients with benign diseases such as BPH,
ureter stone and stress urinary incontinence after in-
formed consent. All control tissues were histologically
confirmed as normal. Patients with concomitant carcin-
oma in situ, a short term follow-up period (less than
6 months), or for whom there was incomplete data col-
lection were excluded in order to make the study popu-
lation more homogeneous. The cohort 1 was consisted
of 305 (253 male and 52 female with average age,
65 years old) BC patients and 34 controls (19 male and
15 female with average age, 54 years old), and the inde-
pendent cohort 2 was consisted of 140 BC patients. All
tumors were macro-dissected, typically within 15 min of
surgical resection. Each bladder cancer specimen was
confirmed by pathological analysis of a part of the tissue
sample in fresh frozen sections from TUR or cystectomy
specimens, and was then frozen in liquid nitrogen and
stored at −80 °C until use. In the case of NMIBC, a sec-
ond TUR was performed 2–4 weeks after the initial re-
section if a bladder cancer specimen did not include the
proper muscle or when a high-grade tumor was de-
tected. Patients who had a T1 tumor, multiple tumors,
large tumors (>3 cm in diameter), or high grade Ta
NMIBC received one cycle of intravesical treatment
(e.g., 6-weekly treatment of BCG or 8-weekly treatment
of mitomycin-C). Response to treatment was assessed by
cystoscopy and urinary cytology. Patients who were free
of disease within 3 months after treatment were assessed
every 3 months for the first 2 years and then every
6 months thereafter. In the case of MIBC, patients with
clinically localized or locally advanced tumors and good
ECOG performance status (0 or 1) underwent radical
cystectomy and complete pelvic lymph node dissection
using an extended lymphadenectomy. Patients who were
not eligible for radical cystectomy due to metastatic dis-
ease, poor life expectancy, or poor ECOG performance
status (≥2) underwent TUR or biopsy for histopathological
diagnosis. Patients with pT3, pT4 or node-positive disease
based on the analysis of radical cystectomy specimens,
or with metastatic disease but good performance status,
received at least four cycles of cisplatin-based chemo-
therapy. Patients who refused or did not complete an
imaging work-up such as a CT scan or MRI at least
once every 3 months to evaluate response also were ex-
cluded from analysis.
Tumors were staged and graded according to the 2002
TNM classification and the EAU guideline based on
1973 WHO grading system [20–22]. Recurrence was de-
fined as recurrence of primary NMIBC with a lower or
the same pathological stage, and progression was defined
as disease with T2 and higher stage upon relapse in
NMIBC. In case of MIBC, progression was defined as
local regional recurrence or a new distant metastasis in
the cystectomized group and a ≥ 20 % increase in the
mass of the primary tumor or a new distant metastasis
in the non-cystectomized group.
RNA extraction and construction of cDNA
RNA was isolated from tissue using 1 ml of TRIzol
(Invitrogen, Carlsbad, CA) with homogenization in a 5-
ml glass tube. The homogenate was transferred to a
1.5-ml tube and then mixed with 200 ml of chloroform.
After incubation for 5 min at 4 °C, the homogenate was
centrifuged for 13 min at 13,000 g at 4 °C. The upper
aqueous phase was transferred to a clean tube with
500 ml of isopropanol. The mixture was incubated for
60 min at 4 °C followed by centrifugation for 8 min at
13,000 g, 4 °C. The upper aqueous phase was discarded
and mixed with 500 ml of 75 % ethanol, and centri-
fuged for 5 min at 13,000 g, 4 °C. The upper aqueous
layer was discarded and the pellet was dried at room
temperature, dissolved in DEPC-treated water, and then
stored at −80 °C. The quality and integrity of the RNA
were confirmed using Nanodrop. cDNA was prepared
from 1 mg of total RNA using a First-Strand cDNA
Synthesis Kit (Amersham Biosciences Europe GmbH,
Freiburg, Germany) according to the manufacturer’s
protocol.
Real-time PCR
Real-time PCR amplification was performed using a Rotor
Gene 6000 instrument (Corbett Research, Mortlake,
Australia) to quantify the expression of USP2a mRNA.
Real-time PCR assays were carried out in micro-reaction
tubes (Corbett Research, Mortlake, Australia) using SYBR
Premix EX Taq (TAKARA BIO INC., Otsu, Japan). The
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following primers were used to determine USP2a mRNA
levels: forward 5′-TGCTGAGACCCGACATCACT-3′; re-
verse 5′-TGGGGTCTATCCGGTAGCTA-3′, as described
in previous literature [12]. The PCR reaction was per-
formed in a final volume of 10 ml consisting of 5 ml of 2
X SYBR premix EX Taq buffer, 0.5 ml each of 59- and 39-
primer (10 pmol/ml), and 1 ml of the sample cDNA. The
product was purified with a QIAquick Extraction kit
(QIAGEN, Hilden, Germany), quantified with a spectro-
photometer (Perkin Elmer MBA2000, Fremont, CA), and
then sequenced with an automated laser fluorescence
sequencer (ABI PRISM 3100 Genetic Analyzer, Foster
City, WI). Ten-fold serial dilutions of a known concen-
tration of the product (from 100 pg/ml to 0.1 pg/ml)
were used to establish the standard curve for real-time
PCR. The real-time PCR conditions were as follows:
1 cycle for 20 s (seconds) at 96 °C, followed by 40 cycles
of 2 s at 96 °C for denaturation, 15 s at 60 °C for an-
nealing, and 15 s at 72 °C for extension. The melting
program was performed at 72–95 °C with a heating rate
of 1 °C per 45 s. Spectral data were captured and ana-
lyzed using Rotor-Gene Real-Time Analysis Software
6.0 Build 14 (Corbett Research, Mortlake, Australia).
All samples were run in triplicate. Glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) was analyzed as an
endogenous RNA reference gene and gene expression
was normalized to the expression of GAPDH.
Statistical Analysis
Differences in continuous variables between groups were
assessed by one-way ANOVA analysis.
Results
Clinical and pathological characteristics of patients with
bladder cancer
A previous study from our laboratory presented evidence
suggesting that the USP2a deubiquitinase plays a role in
bladder cancer cell proliferation using a cell culture system
[11]. In order to approach the question of whether USP2a
is involved in bladder cancer progression and aggressive-
ness, we analyzed USP2a mRNA expression level by qRT-
PCR using human specimens from 305 patients with blad-
der cancer and 34 age-matched controls. Expression levels
were compared to various clinical bladder cancer character-
istics including grade (G), stage (T, N and M), tumor size,
recurrence, progression, and cancer specific survival. The
characteristics of the cancer patients and controls are
shown in Table 1, and further comparisons were performed
in separately categorized NMIBC and MIBC groups.
The level of USP2a mRNA expression as a diagnostic
marker for bladder cancer
USP2a mRNA expression in bladder cancer patients was
significantly reduced (81.4 %) with respect to non-cancer
patient controls (p < 0.001). The reduction in MIBC
(n = 121) when compared to NMIBC (n = 184) was
36.3 % (p = 0.004) (Table 2). To further evaluate the re-
duction of USP2a during bladder cancer progression, we
performed another qRT-PCR analysis using the second co-
hort, which is consisted with independent 140 patients
(Table 3). BC tissues and adjacent normal bladder tissues
from same patients were collected. In the cohort 2, USP2a
mRNA expression of BC tissues was significantly decreased
Table 1 Clinical and pathological features of patients with
bladder cancer and controls
Variables No. of
patients (%)
No. of
controls (%)
No. 305 34
Mean age ± SD 65.0 ± 12.6 53.8 ± 14.9
Gender
Male 253 (83.0) 19 (55.9)
Female 52 (17.0) 15 (44.1)
Grade
G1 56 (18.4)
G2 132 (43.3)
G3 117 (38.4)
T stage
Ta 48 (15.7)
T1 136 (44.6)
T2 55 (18.0)
T3 38 (12.5)
T4 28 (9.2)
N stage
N0 274 (89.8)
N(1–3) 31 (10.2)
M stage
M0 287 (94.1)
M1 18 (5.9)
Median follow-up period (months)
SD standard deviation
Table 2 Levels of mRNA expression of USP2a were compared
between bladder cancer and controls’ mucosae (Cohort 1)
Variables Patients mRNA expression
of USP2a (median with
IQR; × 103 copies/μl)
p value
Cancer vs. controls’ mucosae <0.001
Controls 34 825.6 (370.1–1767.7)
Cancer 305 153.9 (50.2–435.1)
NMIBC vs. MIBC 0.004
NMIBC 184 180.2 (66.6–395.8)
MIBC 121 114.8 (23.7–477.0)
IQR interquartile range; NMIBC non-muscle invasive bladder cancer; MIBC
muscle invasive bladder cancer
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in comparison to matched surrounding normal mucosae
(p < 0.001) (Table 3). The reduction of USP2a mRNA ex-
pression in cancerous tissues was 86.9 %, which was similar
to that seen in the first cohort in comparison to healthy
controls (Table 2).
USP2a mRNA expression is significantly correlated to high
stage of MIBC
With respect to several clinicopathological variables (e.g.
age, sex, tumor size, number, grade, stage, and USP2a
mRNA expression levels), low USP2a mRNA expression
level was likely to reflect a significant risk of high stage
(p = 0.024) in patients with MIBC, but not in NMIBC
(Table 4). MIBC patients at higher stages such as T4 or
N > 1 or M1 exhibited 52.5 % reduced USP2a expression,
compared to MIBC patients at lower stages such as T2,
T3, N0 or M0 (Table 4). However, no significant alteration
of USP2a level was observed according to grades (Table 4).
These data suggest that USP2a expression can be used
specifically as a potential marker to stratify MIBC at
higher stage.
To test whether USP2a can be developed as a progno-
sis- or clinical outcome-related classifier, individual ana-
lyses were performed based on clinical outcomes (e.g.
recurrence, progression, and overall survival). Analysis
was performed with 118 NMIBC patients with no recur-
rence vs. 66 with recurrence, 162 NMIBC patients with
no progression vs. 22 with progression, 38 MIBC pa-
tients with no progression vs. 83 with progression, and
49 alive MIBC patients vs. deceased 72 subjects (Table 5).
Both in NMIBC and MIBC groups, we could not detect
significant differences in USP2a expression when com-
paring recurrence (p = 0.756 for NMIBC), progression
(p = 0.793 for NIBMC, and p = 0.912 for MIBC), and
overall survival (p = 0.123 for MIBC).
Collectively, these data suggest that (1) USP2a level
may be used for stratification of cancer from normal, or
NMIBC from MIBC, (2) USP2a expression is not signifi-
cantly associated with recurrence, progression or overall
patient survival of NMIBC as well as MIBC.
Discussion
Our results suggest that quantification of USP2a gene
expression in bladder tumors may help differentiate nor-
mal vs. cancer, superficial vs. muscle invasive, and early
MIBC vs. more advanced MIBC, when combined with
traditional pathological testing and imaging. Analysis
was conducted using 305 tissue specimens of bladder
cancer patients with 34 age-matched controls, and 184
NMIBC and 121 MIBC patient tissues. A correlation be-
tween USP2a level and cancer is supported by analysis
of a second cohort consisted of 140 bladder cancer spec-
imens and their surrounding normal tissues. To our
Table 3 Comparisons of USP2a expression and
clinopathological features of bladder cancer (Cohort 2)
Variables Patients mRNA expression of
USP2a (median with
IQR; × 103 copies/μl)
P value
Cancer vs. matched
surrounding tissue
<0.001
Surrounding tissue 140 1051.2 (403.4–2212.3)
Cancer 140 138.1 (53.9–445.6)
IQR interquartile range
Table 4 Comparisons of USP2a expression and
clinopathological features of bladder cancer
Variable Patient (%) mRNA expression of
USP2a (median with
IQR; × 10^3 copies/μl)
p value
Grade 0.666
G1 56 (18.4) 186.4 (68.7–345.0)
G2 132 (43.3) 151.4 (47.3–463.2)
G3 117 (38.4) 137.3 (40.4–502.4)
NMIBC 0.681
Ta 48 (26.1) 160.3 (68.7–340.2)
T1 136 (73.9) 184.7 (65.4–489.5)
MIBC 0.024
T2 or T3, N0, M0 67 (55.4) 136.7 (41.6–567.2)
T4 or N ≥1 or M1 54 (44.6) 71.7 (15.8–296.1)
IQR interquartile range; NMIBC non muscle invasive bladder cancer; MIBC
muscle invasive bladder cancer
Table 5 Comparisons of USP2a expression and clinical
outcomes of bladder cancer patients
Variables Patients (%) mRNA expression of
USP2a (median with
IQR; × 10^3 copies/μl)
p value
NMIBC
Recurrence 0.756
No recurrence 118 (64.1) 200.2 (77.9–391.7)
Recurrence 66 (35.9) 157.6 (56.4–387.2)
Progression 0.793
No progression 162 (88.0) 165.5 (65.0–355.3)
Progression 22 (12.0) 238.9 (58.7–122.3)
MIBC
Progression 0.912
No progression 38 (31.4) 112.6 (23.1–508.7)
Progression 83 (68.6) 115.2 (22.9–435.1)
Overall survival 0.123
Alive 49 (40.5) 81.3 (16.1–483.3)
Death 72 (59.5) 128.3 (37.4–494.1)
IQR interquartile range; NMIBC non-muscle invasive bladder cancer; MIBC
muscle invasive bladder cancer
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knowledge, this study presents the largest clinical data
set describing USP2a gene expression in bladder cancer.
The patient-based results in this study suggest that
USP2a expression was downregulated in bladder cancer
tissues, which was inconsistent to previous in vitro studies
implying the positive correlation of aggressiveness and
USP2a [11, 12]. This discrepancies may be also explained
by different and as yet poorly understood biological roles
of USP2a, which is dependent on physiologic environment
and cell context, or it may be the result of the natural
composition of human specimens that include epithelial,
stromal or inflammatory cells, and their communication
with tumor cells.
There have been recent landmark studies defining the
molecular phenotypes of bladder cancer, which may pro-
vide understanding the molecular and genetic events
underlying BC progression. At least 3-4 molecular sub-
types of BC were identified based on distinct mutations,
and gene expression signatures, which may be connected
to sensitivity to chemotherapy. The basal type BC sub-
group expressing basal markers was dependent on the
EGFR signaling pathway, thus this subgroup was signifi-
cantly sensitive to treatment with drugs that inhibit the
EGFR pathway. EGFR, a potential prognostic marker for
MIBC has also been widely studied in bladder cancer
[18]. Up-regulated EGFR signaling is known to initiate a
cascade of events and lead to cell proliferation, migra-
tion, invasion and inhibition of apoptosis, all of which
promotes tumor progression [23]. Altered expression of
EGF family members (e.g. EGF, epiregulin and HB-EGF
(heparin-binding epidermal growth factor-like growth
factor)) and EGFR has been suggested as mediators of
bladder cancer progression [24]. We showed previously
that HB-EGF accumulates in the nucleus in aggressive
TCC cells and is involved in an EGFR-dependent autocrine
loop [24, 25], and that USP2a increases EGFR stability by
inhibiting endocytosis and degradation of EGFR [10]. Based
on the published literatures and the present data, EGFR and
USP2a levels may be correlated with disease progression, al-
though this has not been evaluated in the same series of tu-
mors. A next step is to determine whether altered levels of
EGFR [18] and USP2a are correlated with more aggressive
bladder cancer, and whether these combined two mo-
lecular markers might predict aggressive disease.
Collectively, there is a critical need for methods that
identify patients with MIBC that are likely to experience
disease progression or metastasis. Our study demonstrated
that USP2a expression levels make it possible to distin-
guish bladder cancer from normal, and muscle-invasive
from non-invasive disease.
Conclusions
The experimental results in this study provide an evidence
suggesting that USP2a as a biomarker may improve
diagnosis of human bladder cancer patients. Although
the present analyses were performed with a large series of
bladder cancer patients, which were carefully grouped into
NMIBC vs. MIBC based on clinical evaluation, a larger
prospective validation of our findings should be
attempted.
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